Patients who respond to anti-PD-1 therapy exhibit a tumor micro-environment that is enriched for interferon γ (IFNγ) and tumor infiltrating lymphocytes (TILs), the so called ‘hot’ tumors [11,12,13]. This evidence concerns the gene PDCD1 and neoplasm.